(-)-Anonaine induces DNA damage and inhibits growth and migration of human lung carcinoma h1299 cells. 2011

Bing-Hung Chen, and Hsueh-Wei Chang, and Hsuan-Min Huang, and Inn-Wen Chong, and Jia-Shing Chen, and Chung-Yi Chen, and Hui-Min Wang
Department of Biotechnology, Kaohsiung Medical University, and Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan.

The anticancer effects of (-)-anonaine were investigated in this current study. (-)-Anonaine at concentration ranges of 50-200 μM exhibited significant inhibition to cell growth and migration activities on human lung cancer H1299 cells at 24 h, albeit cell cycle analyses showed that (-)-anonaine at the above concentration ranges did not cause any significant changes in cell-cycle distributions. Significant nuclear damages of H1299 cells were observed with 10-200 μM (-)-anonaine treatment in a comet assay, whereas higher concentrations (6 and 30 mM) of (-)-anonaine concentrations were required to cause DNA damages in an in vitro plasmid cleavage assay. In summary, our results demonstrated that (-)-anonaine exhibited dose-dependent antiproliferatory, antimigratory, and DNA-damaging effects on H1299 cells. We inferred that (-)-anonaine can cause cell-cycle arrest and DNA damage to hamper the physiological behavior of cancer cells at 72 h, and therefore, it can be useful as one of the potential herbal supplements for chemoprevention of human lung cancer.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D004149 Dioxoles
D004249 DNA Damage Injuries to DNA that introduce deviations from its normal, intact structure and which may, if left unrepaired, result in a MUTATION or a block of DNA REPLICATION. These deviations may be caused by physical or chemical agents and occur by natural or unnatural, introduced circumstances. They include the introduction of illegitimate bases during replication or by deamination or other modification of bases; the loss of a base from the DNA backbone leaving an abasic site; single-strand breaks; double strand breaks; and intrastrand (PYRIMIDINE DIMERS) or interstrand crosslinking. Damage can often be repaired (DNA REPAIR). If the damage is extensive, it can induce APOPTOSIS. DNA Injury,DNA Lesion,DNA Lesions,Genotoxic Stress,Stress, Genotoxic,Injury, DNA,DNA Injuries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077192 Adenocarcinoma of Lung A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer. Lung Adenocarcinoma,Adenocarcinoma, Lung,Adenocarcinomas, Lung,Lung Adenocarcinomas
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D001060 Aporphines Dibenzoquinolines derived in plants from (S)-reticuline (BENZYLISOQUINOLINES).
D015536 Down-Regulation A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Down-Regulation,Down-Regulation (Physiology),Downregulation,Down Regulation,Down-Regulation, Receptor

Related Publications

Bing-Hung Chen, and Hsueh-Wei Chang, and Hsuan-Min Huang, and Inn-Wen Chong, and Jia-Shing Chen, and Chung-Yi Chen, and Hui-Min Wang
January 2020, Journal of Cancer,
Bing-Hung Chen, and Hsueh-Wei Chang, and Hsuan-Min Huang, and Inn-Wen Chong, and Jia-Shing Chen, and Chung-Yi Chen, and Hui-Min Wang
January 2020, Biological & pharmaceutical bulletin,
Bing-Hung Chen, and Hsueh-Wei Chang, and Hsuan-Min Huang, and Inn-Wen Chong, and Jia-Shing Chen, and Chung-Yi Chen, and Hui-Min Wang
June 2020, Oncology reports,
Bing-Hung Chen, and Hsueh-Wei Chang, and Hsuan-Min Huang, and Inn-Wen Chong, and Jia-Shing Chen, and Chung-Yi Chen, and Hui-Min Wang
January 2013, International journal of clinical and experimental pathology,
Bing-Hung Chen, and Hsueh-Wei Chang, and Hsuan-Min Huang, and Inn-Wen Chong, and Jia-Shing Chen, and Chung-Yi Chen, and Hui-Min Wang
January 2009, Oncogene,
Bing-Hung Chen, and Hsueh-Wei Chang, and Hsuan-Min Huang, and Inn-Wen Chong, and Jia-Shing Chen, and Chung-Yi Chen, and Hui-Min Wang
November 2013, Cancer gene therapy,
Bing-Hung Chen, and Hsueh-Wei Chang, and Hsuan-Min Huang, and Inn-Wen Chong, and Jia-Shing Chen, and Chung-Yi Chen, and Hui-Min Wang
December 2019, Molecules (Basel, Switzerland),
Bing-Hung Chen, and Hsueh-Wei Chang, and Hsuan-Min Huang, and Inn-Wen Chong, and Jia-Shing Chen, and Chung-Yi Chen, and Hui-Min Wang
December 2016, Environmental toxicology,
Bing-Hung Chen, and Hsueh-Wei Chang, and Hsuan-Min Huang, and Inn-Wen Chong, and Jia-Shing Chen, and Chung-Yi Chen, and Hui-Min Wang
September 2015, Environmental toxicology,
Bing-Hung Chen, and Hsueh-Wei Chang, and Hsuan-Min Huang, and Inn-Wen Chong, and Jia-Shing Chen, and Chung-Yi Chen, and Hui-Min Wang
September 2006, Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology,
Copied contents to your clipboard!